BioSpace News Archive

Detailed characterization of an oral inhibitor of CDK7 demonstrates potent activity against multiple hematologic and solid tumor cell lines, as monotherapy and in combination with chemotherapies

ORIC Pharmaceuticals, Inc. announced a poster presentation and oral discussion at the upcoming 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held virtually October 24 - 25, 2020.

The German Breast Group and Pfizer Inc. announced that the collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival in women with hormone receptor-positive, human epidermal growth factor-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy.

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, announced that it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for AXO-AAV-GM1, an AAV9-based gene therapy delivered via a single intravenous administration that is in Phase 1/2 development for GM1 gangliosidosis.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (“Lilly”, NYSE: LLY),

Athenex, Inc. (NASDAQ: ATNX), today announced that Athenex Oncology, a U.S. based division of Athenex, launched Your Guide to Facing Metastatic Breast Cancer -- a free, first-of-its-kind resource offering comprehensive lifestyle guidance to people living with metastatic breast cancer (MBC)

Loki Therapeutics, an immuno-oncology company developing next-generation cancer therapeutics that leverage childhood vaccination recall antigens, announced that Chris Bradley, CEO and co-founder, will present an overview of the company’s scientific and clinical plans at 2020 BIO Investor Forum Digital 2020,

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel’s oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of preclinical research in an influenza animal model highlighting a new mechanism for enhancing the efficacy of monoclonal antibodies to treat viral infection and induce a protective response

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed with TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, administered alone and in combination with ipilimumab and nivolumab, in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors.